GVR Report cover U.S. Blood Ketone Meter Market Size, Share & Trends Report

U.S. Blood Ketone Meter Market (2025 - 2033) Size, Share & Trends Analysis Report By Type (Blood Ketone Monitoring, Blood Glucose and Ketone Monitoring, Consumables), By Application, By End Use, And Segment Forecasts

U.S. Blood Ketone Meter Market Summary

The U.S. blood ketone meter market size was estimated at USD 106.1 million in 2024 and is projected to reach USD 115.1 million by 2033, growing at a CAGR of 0.9% from 2025 to 2033. Some of the factors contributing to market growth include the increasing prevalence of diabetes, growing health awareness among consumers and rising adoption of ketogenic and low-carbohydrate diets.

Key Market Trends & Insights

  • By type, the blood glucose and ketone monitoring segment held the highest market share of 51.6% in 2024.
  • Based on application, the human segment held the highest market share in 2024.
  • By end use, the hospital segment held the highest market share in 2024.

Market Size & Forecast

  • 2024 Market Size: USD 106.1 Million
  • 2033 Projected Market Size: USD 115.1 Million
  • CAGR (2025-2033): 0.9%
Ask a question about the U.S. blood ketone meter market
Try asking
✓Every figure cited from GVR research Prefer the report? Download free sample →


The growth is driven by increasing interest in metabolic health management, particularly within the keto diet community and among people who need to monitor Blood ketone meters are used to monitor ketone levels for managing Type 1 Diabetes (T1D), tracking nutritional ketosis in ketogenic diets, and supporting the treatment of neurological conditions such as epilepsy. A 2023 study titled “Point-of-Care Capillary Blood Ketone Measurements and the Prediction of Future Ketoacidosis Risk in Type 1 Diabetes” investigated whether routine point-of-care capillary blood ketone measurements in fasted, symptom-free individuals with T1D could predict future DKA events.

U.S. blood ketone meter market size and growth forecast (2023-2033)Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, icon Download Free Sample Report

The findings showed that routine capillary ketone monitoring can help identify individuals at elevated risk of future DKA, highlighting the potential value of emerging technologies such as Continuous Ketone Monitoring (CKM) for early intervention and prevention. With the growing awareness of DKAprevention, such evidence will likely broaden the adoption and expansion of the U.S. blood ketone meter market.

The U.S. blood ketone meter industry is shaped by evolving care delivery models and payer policy reforms. The rise of telehealth, boosted significantly by the COVID-19 pandemic, has made diabetes management more accessible by enabling remote consultations, real-time data sharing, and timely treatment adjustments. This shift supports more consistent use of monitoring tools such as blood ketone meters, especially for patients managing T1D or adhering to ketogenic therapies. In 2024, approximately 20,000 children and adolescents under the age of 20 in the U.S. were newly diagnosed with T1D. This increase is driven by inherited risk, environmental factors, and changes in early-life habits (such as diet and infections).

The MDPI 2025 study titled “Severe Diabetic Ketoacidosis in Children with Type 1 Diabetes” highlighted key findings on ketone monitoring. The study found that blood ketone testing was more effective than urine ketone testing in early DKA detection and management.

Type Insights

The blood glucose and ketone monitoring segment dominated the U.S. blood ketone meter industry and accounted for a revenue share of 51.6% in 2024, owing to the rising prevalence of T1D, increased awareness of DKA prevention, and growing adoption of ketogenic diets for metabolic health and weight management. Advances in dual-function devices that measure glucose and ketones from a single meter have enhanced convenience and patient compliance. In addition, the expansion of telehealth, improvements in insurance coverage for remote monitoring tools, and the integration of digital health platforms are making ketone tracking more accessible and clinically actionable. These advancements collectively support better chronic disease management and fuel broader acceptance of health-monitoring wearables across the healthcare system. In June 2024, the U.S. Department of Health and Human Services (HHS) announced plans to launch a major campaign encouraging the use of wearable health devices to monitor metrics such as glucose and heart rate. The initiative aims to promote self-health management and reduce reliance on costly medications, envisioning nationwide adoption within 4 years.

The blood ketone monitoring segment is expected to grow at the fastest CAGR of 1.3% over the forecast period. Traditionally, ketone levels have been measured through occasional finger-stick tests, but this method often misses the early stages of ketone buildup, which can lead to diabetic ketoacidosis. There has been research, clinical interest, and industry investment in CKM devices, with prototypes already under development and expected to become commercially available shortly.

Application Insights

The human segment accounted for the highest revenue share in 2024. The growing popularity of ketogenic diets for weight loss, epilepsy management, and metabolic health has led health-conscious individuals to adopt personal ketone monitoring tools. Rising awareness of early DKA symptoms, advancements in user-friendly at-home testing devices, and expanding telehealth services have made it easier for individuals to self-monitor and share ketone data with healthcare providers.

The veterinary segment is expected to grow over the forecast period. This is owing to the rising incidence of metabolic disorders such as bovine ketosis in dairy cattle and DKA in companion animals such as dogs and cats. Increased awareness among veterinarians and livestock owners about the economic and health impacts of delayed diagnoses has led to a greater adoption of point-of-care ketone testing. Advancements in portable and easy-to-use veterinary-specific ketone meters have made monitoring more accessible for veterinarians and pet owners.

End Use Insights

The hospitals segment accounted for the largest revenue share in 2024. Hospitals rely on rapid point-of-care ketone testing for timely diagnosis and treatment, especially in emergency, ICU, and pediatric settings. The growing demand for portable devices that offer immediate results and integrate with electronic medical records supports clinical efficiency and coordinated care.

U.S. Blood Ketone Meter Market Share

To learn more about this report, icon Download Free Sample Report

The home care settings segment is expected to experience the fastest CAGR over the forecast period. With more individuals managing type 1 diabetes, following ketogenic diets, or using insulin therapies, the need for convenient, accurate at-home ketone testing is increasing. Recent advancements in portable meter accuracy and expanded online access through e-commerce platforms have boosted consumer confidence and convenience, reinforcing the market shift toward home-based metabolic care.

Key U.S. Blood Ketone Meter Company Insights

Some key players in the U.S. blood ketone meter industry are TaiDoc Technology Corporation, EKF Diagnostics Holdings plc, and Abbott.

  • TaiDoc specializes in medical diagnostic and monitoring devices, with a strong presence in the U.S. home and clinical care markets. Its portfolio includes multi-function meters that measure blood glucose and ketones, catering to individuals managing diabetes and those following ketogenic therapies.

Key U.S. Blood Ketone Meter Companies:

  • Abbott
  • Apex Biotechnology Corp.
  • TaiDoc Technology Corporation
  • EKF Diagnostics Holdings plc.
  • Nova Biomedical
  • Keto-Mojo
  • ForaCare, Inc.
  • Nipro
  • i-SENS, Inc

Recent Developments

  • In 2024, Nova Biomedical launched its next-generation StatStrip Glucose/Ketone Hospital Meter in the U.S. It is the only FDA-cleared glucose meter for all critically ill patient samples and helps measure blood ketones.

U.S. Blood Ketone Meter Market Report Scope

Report Attribute

Details

Market size value in 2025

USD 107.1 million

Revenue forecast in 2033

USD 115.1 million

Growth rate

CAGR of 0.9% from 2025 to 2033

Historical Period

2021 - 2023

Actual data

2024

Forecast period

2025 - 2033

Quantitative units

Revenue in USD million/billion and CAGR from 2025 to 2033

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Type, application, end use

Key companies profiled

Abbott; Apex Biotechnology Corp.; TaiDoc Technology Corporation; EKF Diagnostics Holdings plc.; Nova Biomedical; Keto-Mojo; ForaCare, Inc.; Nipro; i-SENS, Inc.

Customization scope

Free report customization (equivalent up to 8 analyst working days) with purchase. Addition or alteration to segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

U.S. Blood Ketone Meter Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. blood ketone meter market report based on type, application, and end use:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)

    • Blood Ketone Monitoring

    • Blood Glucose and Ketone Monitoring

    • Consumables

  • Application Outlook (Revenue, USD Million, 2021 - 2033)

    • Humans

    • Veterinary

  • End Use Outlook (Revenue, USD Million, 2021 - 2033)

    • Hospitals

    • Diagnostic Centers

    • Home Care Settings

    • Other

About the Author(s)

Medical Devices Research Team

Healthcare · Medical Devices

This report was authored by the medical devices research team at Grand View Research - comprising two research analysts, one senior research analyst, and one industry expert - with specialized expertise in the medical devices segment of the healthcare industry. All findings are based on proprietary healthcare databases, executive interviews, and regulatory analysis, subject to internal peer review prior to publication.

Last Updated:

Speak to Analyst

Trusted market insights - try a free sample

See how our reports are structured and why industry leaders rely on Grand View Research. Get a free sample or ask us to tailor this report to your needs.

logo
GDPR & CCPA Compliant
logo
ISO 9001 Certified
logo
ISO 27001 Certified
logo
ESOMAR Member
Grand View Research is trusted by industry leaders worldwide
client logo
client logo
client logo
client logo
client logo
client logo